Ten ways multiple myeloma treatment is changingAs multiple myeloma treatment improvements continue, it’s important for managed care executives to get out in front of these 10 changes on the horizon.
FDA warns about deaths in cancer drug trials
FDA warns about deaths in cancer drug trialsAn increased risk of deaths for patients in clinical trials receiving this cancer drug and two other drugs led FDA to stop the clinical trials.
Large variety of multiple myeloma treatment options presents challengesThere now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study
FDA approves a new immune-stimulating drug to treat multiple myelomaFDA has approved elotuzumab (Empliciti, Bristol-Myers Squibb and AbbVie) for the treatment of multiple myeloma.
FDA approves first immunostimulatory antibody for multiple myelomaAn oncology expert at ASH will present extended follow-up and overall survival data from ELOQUENT-2, the study on which Empliciti is approved.
Top 5 things to know about new myeloma drugIn FDA’s latest approval of a new medication to treat multiple myeloma, the agency approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
FDA expands approval of Revlimid to include newly diagnosed multiple myelomaFDA expanded approval of lenalidomide (Revlimid, Celgene) for the treatment of multiple myeloma. Revlimid acts as an immunomodulating agent and inhibits the growth of myeloma cells by inducing cell cycle arrest and cell death.
Proteasome inhibitor meets primary end point of improvement in PFS in relapsed or refractory multiple myelomaA pivotal phase 3 trial evaluating the safety and efficacy of investigational ixazomib (Takeda), the first oral proteasome inhibitor (PI), conducted in patients with relapsed or refractory multiple myeloma achieved its primary end point of improving progression-free survival (PFS) at the first pre-specified interim analysis.
FDA drug approvals-February 2015FDA actions in brief, priority review, breakthrough designations, orphan drug designations
Updated data with oral proteasome inhibitor reported in newly diagnosed multiple myeloma patientsAn investigational all-oral proteasome inhibitor—MLN9708 (Millennium: The Takeda Oncology Company)—plus lenalidomide and dexamethasone generated high response rates and increased depth of response with extended treatment duration in newly diagnosed multiple myeloma patients, according to data presented at the American Society of Hematology (ASH) 2013 annual meeting in New Orleans.